Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Manisha Palta, MD, Duke University Cancer Center
Videos
An Argument for Radiation in the Neoadjuvant Setting for Pancreatic Cancer
03/23/2023
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation...
03/23/2023
Oncology
Gerard Morton, MD, Odette Cancer Center at Sunnybrook Research Institute
Videos
Methods of Radiation Dose Intensification for High-Risk Prostate Cancer
03/21/2023
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation...
03/21/2023
Oncology
Mylin Torres, MD, Winship Cancer Institute
Videos
Five-Fraction Radiation Regimens for Early-Stage Breast Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
Chemoimmunotherapy and the Changing Landscape of Preoperative Treatment for Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
How Preoperative Chemoimmunotherapy May Change Management of Patients With Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Quiz
Quiz: Does Metoformin, CCRT Combo Improve OS in NSCLC?
03/30/2022
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a...
03/30/2022
Oncology
Adding Metformin to CCRT Does Not Improve Survival in NSCLC
03/23/2022
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to...
03/23/2022
Oncology
Quiz
Quiz: Does Nivolumab Impact Surgical Outcomes in Residual Disease?
03/16/2022
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at...
03/16/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Dr Chuong
Videos
Dr Chuong Highlights Ablative MR-Guided Radiation Therapy in Inoperable Pancreatic Cancer
10/04/2021
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer...
10/04/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
Interview
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
01/28/2020
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS,...
01/28/2020
Oncology

Advertisement

Advertisement

At the Radiation Oncology Summit: ACRO, attendees can learn about the latest research updates in radiation oncology and network with like-minded colleagues in the radiology space.

What Your Colleagues are Reading

James Harding, MD
Conference Coverage
Transarterial Chemoembolization Plus Immune Checkpoint Blockade for Patients With Hepatocellular Carcinoma
05/22/2024
James Harding, MD
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that transarterial chemoembolization plus immune checkpoint blockade...
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that transarterial chemoembolization plus immune checkpoint blockade...
At Great Debates and Updates in...
05/22/2024
Oncology
Videos
Dr Bruno Highlights Racial Disparities in Testing, Trial Enrollment in NSCLC
06/07/2021
Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.
Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.
Dr Bruno, MD, discusses the...
06/07/2021
Oncology
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
Podcasts
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
04/23/2021
Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.
Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.
Nakia Spencer, MSc, discusses...
04/23/2021
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
Allison Casey
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
Dr Tagawa
Videos
Dr Tagawa Discusses Study Results of Actinium J591 for mCRPC
06/22/2021
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP,...
06/22/2021
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement